Full-Time
Manager – Medical Writing
Immunology
Updated on 8/7/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
High Wycombe, UK
In Person
Remote work options may be considered on a case-by-case basis.
Bachelor's, Master's, PhD
 Content & Writing (2) |
|---|
| , |
Get referred to Johnson & Johnson
See people who can refer or advise you
- Minimum of University/college degree required.
- Prepare and finalize all types of clinical documents.
- Lead in a team environment. Work with a high level of independence and take a lead role on assigned projects with respect to content and scientific strategy, timing, scheduling, and tracking.
- Lead or set objectives for others on team projects and tasks, e.g., lead process working groups.
- Guide or train cross-functional team members on processes and best practices.
- May lead project-level/submission/indication writing teams.
- Proactively provide recommendations for departmental process improvements.
- If a lead writer for a program: Primary point of contact and champion for medical writing activities for the clinical team. Responsible for planning and leading the writing group for assigned program.
- Actively participate in medical writing and cross-functional meetings.
- Maintain knowledge of industry, company, and regulatory guidelines.
- Coach or mentor more junior staff on document planning, processes, content, and provide peer review as needed; may oversee the work of other medical writers, external contractors, and document specialists supporting a project.
- May interact with senior cross-functional colleagues to strengthen coordination between departments.
- May represent Medical Writing department in industry standards working groups.
- Manage direct reports in Medical Writing. Set objectives for individual team members. Regularly meet with direct reports to ensure appropriate development, projects, assignments, and issues are resolved.
- Make decision on hiring staff, onboarding new staff, conducting career and talent development discussions for staff, lead in goal-setting, and performance discussions.
- Masters or PhD in a related field (Education)
- At least 8 years of relevant pharmaceutical/scientific experience; at least 6 years of relevant medical writing experience is required.
- 2 years of people management experience is required.
- Attention to detail.
- Excellent oral and written communication skills are pivotal to engage in cross-functional discussions.
- Expert project/time management skills.
- Strong project/process leadership skills.
- Ability to recognize how to best interpret, summarize, and present statistical and medical information to ensure quality and accuracy of content.
- Able to resolve complex problems independently.
- Demonstrate learning agility.
- Able to build and maintain solid and positive relationships with cross-functional team members.
- Solid knowledge and application of regulatory guidance documents such as ICH requirements.
- Analytics Insights, Business Writing, Clinical Research and Regulations, Clinical Trials Operations, Copy Editing, Cross-Functional Collaboration, Developing Others, Inclusive Leadership, Industry Analysis, Leadership, Medical Affairs, Medical Communications, Performance Measurement, Quality Validation, Standard Operating Procedure, SOP, Tactical Planning, Team Management
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance lifted to $101.1 billion.
- Tremfya grew 72.5% in Q2 2026, offsetting Stelara's patent loss.
- OTTAVA's July 2026 launch plus ongoing hernia trials create a long runway for adoption.
What critics are saying
- Stelara biosimilars and Medicare price cuts pressure immunology revenue throughout 2026.
- Talc settlement still needs 95% claimant approval, and future lawsuits remain outside coverage.
- Abiomed Impella weakness and surgeon skepticism threaten MedTech growth if Q3 volumes stay soft.
What makes Johnson & Johnson unique
- J&J spans pharmaceuticals, MedTech, and consumer health, reducing single-product dependence.
- OTTAVA gained FDA authorization on July 22, 2026, opening a new soft-tissue robotics category.
- AAA credit status and 64-year dividend streak signal exceptional capital discipline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%Johnson & Johnson leads a portfolio of four dividend-growth stocks that together generate $2,304 in annual passive income from a $100,000 investment split equally. The group delivers a 2.30% blended yield. SBA Communications tops the quartet with a 2.58% yield. Johnson & Johnson brings a 64-year dividend streak and AAA credit rating, making it a core income holding. Equinix, which converted to a REIT in 2015, runs the world's largest neutral interconnection footprint. The company generated $2.63 billion in Q2 revenue and has grown its quarterly payout from $2.66 in 2020 to $5.16 today. Institutions own 99.6% of the float. All four stocks trade on major exchanges with tight spreads, offering liquidity advantages over alternatives like rental real estate or mortgage REITs.
Johnson & Johnson returned $85 billion to shareholders over the past five years through $60 billion in dividends and $25 billion in share buybacks, equivalent to 13.8% of its current market capitalisation. The healthcare giant generated $97.93 billion in revenue over the last twelve months with a 27% operating margin. Despite this substantial cash return, JNJ shareholders saw a total return of 70% over five years, underperforming the S&P 500's 83% return. The company's Innovative Medicine division showed strong performance, with double-digit growth excluding STELARA and successful launches like ICOTYDE. However, the MedTech segment struggled, particularly in cardiovascular, where the Abiomed heart pump business saw sales decline 2%. The performance gap between divisions raises questions about whether returning cash signals disciplined capital allocation or a shortage of high-return growth opportunities.
Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.
Johnson & Johnson has agreed to pay $5.5 billion to settle approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires acceptance by at least 95% of claimants to take effect. The company expects to make an initial payment of no more than $3 billion in 2027, with additional payments due from 2028. Legal representatives suggest the total payout could reach $7 billion or more. The deal is designed to deliver payment to all claimants within 18 months and covers only current claims, leaving future lawsuits outside its scope. J&J maintains the claims lack merit but said the settlement allows it to move forward. The agreement follows three years of halted proceedings whilst J&J pursued unsuccessful bankruptcy strategies through a subsidiary. The company withdrew its talc-based baby powder from US shelves in 2020 and worldwide in 2023.
Johnson & Johnson's MedTech segment delivered mixed second-quarter 2026 results. Sales rose 4.5% to $8.93 billion but missed the consensus estimate of $8.96 billion. The shortfall stemmed from weaker cardiovascular performance, particularly in Abiomed, where sales declined 2% due to slow procedural volumes for the Impella heart pump. Physician uncertainty following a UK study questioning Impella's benefit in certain high-risk procedures contributed to reduced usage. Despite cardiovascular weakness, J&J's Surgery, Vision, and Orthopedics businesses accelerated above expectations, growing 3.9%, 6.0%, and 4.9% respectively. Shockwave revenues rose 14.6% to $335 million. J&J characterised the Abiomed issue as temporary and noted stable overall procedure volumes across its MedTech business, with no meaningful impact from expired Affordable Care Act subsidies.